Lucie Guo, MD
Ophthalmology · Philadelphia, PANPI 1679061113
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,403 of the $3,387 with a category attached, or 71.0%. Alcon accounts for 64.7% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2023 at $1,696 and has fallen 90.6% since, to $160 in 2025.
Across 46 payments — averaging $73.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- Astellas Pharma US Inc$280
- Genentech, Inc.$214
- Astellas Pharma Global Development$160
- Biogen$128
- Stryker$123
- plus $292 from 4 others
What the payments were for
- Travel & lodging$98429%
- Food & beverage$2,40371%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 35 | $2,190 |
| Astellas Pharma US Inc | 2 | $280 |
| Genentech, Inc. | 2 | $214 |
| Astellas Pharma Global Development | 1 | $160 |
| Biogen | 1 | $128 |
| Stryker | 1 | $123 |
| Regeneron Healthcare Solutions, Inc. | 1 | $95 |
| Glaukos Corporation | 1 | $86 |
| Regeneron | 1 | $86 |
| Bausch & Lomb Americas Inc. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Izervay$290
- AcrySof IQ PanOptix$226
- AcrySof IQ PanOptix UV IOL$136
- NA$123
- VABYSMO$120
How this compares
$3,387 in reported general payments places this provider in the 70th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 27 | $1,195 |
| Latanoprost | 12 | $75 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Philadelphia
- Julia HallerPhiladelphia$1.5M
- Beeran MeghparaPhiladelphia$496K
- Jonathan MyersPhiladelphia$359K
- Mark BlecherPhiladelphia$357K
- Anton KolomeyerPhiladelphia$355K
- Durga BorkarPhiladelphia$150K
- Rachel NiknamPhiladelphia$142K
- Joseph MarkoffPhiladelphia$130K
- Leslie KatzPhiladelphia$105K
- Zeba SyedPhiladelphia$99K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.